Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00267748 · ClinicalTrials.gov registry record · Phase 2
Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 317
- Enrollment target
NCT00267748 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 317 participants.
The verdict
NCT00267748, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 317 participants
- Enrollment target
Study Summary
This trial has two parts. The purpose of the first part of the trial is to determine the doses of 2 drugs, sunitinib malate and interferon alfa-2b, that can be given safely in combination. This part is currently closed to enrollment. The purpose of the second part of the trial is to see if sunitinib malate given on a 4/2 schedule (4 weeks on treatment, 2 weeks off treatment cycle) is any better at delaying progression of renal cell cancer than sunitinib malate given on a continuous dosing schedule. The trial will also determine the number of patients whose cancer responds to the treatments, whether life of patients can be extended, what the side effects are of the treatments, how bothersome disease or treatment-related symptoms are to patients, and whether tests can be found that will predict which patients may or may not respond to these treatments in the future.
Interventions
- DRUG Sunitinib Malate Continuous Daily Dosing
- DRUG Sunitinib Malate Schedule 4/2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2005-12 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00267748
The ClinicalTrials.gov registry entry for NCT00267748 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 317 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sunitinib Malate Continuous Daily Dosing is the first listed.
NCT00267748 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00267748 about?
NCT00267748 is a clinical study titled "Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)". This trial has two parts. The purpose of the first part of the trial is to determine the doses of 2 drugs, sunitinib malate and interferon alfa-2b, that can be given safely in combination. This part is currently closed to enrollment. The purpose of the second part of the trial is to see if sunitini...
What is the current status of trial NCT00267748?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 317 participants. The study started on 2005-12. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00267748?
The interventions under investigation include: Sunitinib Malate Continuous Daily Dosing (DRUG), Sunitinib Malate Schedule 4/2 (DRUG).
Who is sponsoring clinical trial NCT00267748?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.